Familial Cancer (2014) 13:369–374
DOI 10.1007/s10689-014-9714-7

ORIGINAL ARTICLE

Fertility and apparent genetic anticipation in Lynch syndrome

Douglas Stupart · Aung Ko Win · Mark Jenkins · Ingrid M. Winship · Paul Goldberg · Rajkumar Ramesar

Published online: 28 March 2014

Abstract Genetic anticipation is the phenomenon in which age of onset of an inherited disorder decreases in successive generations. Inconsistent evidence suggests that this occurs in Lynch syndrome. A possible cause for apparent anticipation is fecundity bias, which occurs if the disease adversely affects fertility. The purpose of this study was to determine the effect of age of diagnosis of colorectal cancer (CRC) on lifetime fertility in Lynch syndrome, and whether this can falsely create the appearance of genetic anticipation. A computer model simulated age of diagnosis of CRC in hypothetical Lynch syndrome carriers and their offspring. The model assumed similar age distribution of CRC across generations (i.e. that there was no true anticipation). Age distribution of CRC diagnosis, and lifetime fertility rates (grouped by age of diagnosis of CRC) were determined from the Australasian Colorectal Cancer Family Registry (ACCFR). Apparent anticipation was calculated by comparing ages of diagnosis of CRC in affected parent–child pairs. A total of 1,088 patients with CRC were identified from the ACCFR. Total lifetime (cohort) fertility was related to age of diagnosis of CRC (correlation coefficient 0.13, $P = 0.0001$). In the simulation, apparent anticipation was 1.8 ± 0.54 years ($P = 0.0044$). Observed apparent anticipation in the ACCFR cohort was 4.8 ± 1.73 years ($P = 0.0064$). There was no difference in apparent anticipation between the simulate d and observed parent–child pairs ($P = 0.89$). The appearance of genetic anticipation in Lynch syndrome can be falsely created due to changes in fertility.

Keywords Lynch syndrome · Genetic anticipation · Fertility

D. Stupart (✉)
Deakin University Department of Surgery, Geelong Hospital, Ryrie Street, Geelong, VIC 3227, Australia
e-mail: DouglasStupart@yahoo.co.uk

A. K. Win · M. Jenkins
Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, Australia

I. M. Winship
Genetic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, VIC, Australia

P. Goldberg
Colorectal Unit, Department of Surgery, University of Cape Town, Cape Town, South Africa

R. Ramesar
MRC Human Genetics Research Unit, Division of Human Genetics, Institute for Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Introduction

Lynch syndrome is the commonest known inherited predisposition to colorectal cancer (CRC). CRC risk is inherited in an autosomal dominant manner, caused by germline mutations in the DNA mismatch repair (MMR) genes *MLH1, MSH2, MSH6* and *PMS2*. The age- and gender specific risk of colorectal cancer is increased 20–500-fold [1] and the average age of diagnosis of colorectal cancer decreases from 69 years in the general population [2] to around 45 years [3] in carriers of these mutations.

Genetic anticipation is the phenomenon in which the age of onset of an inherited disorder decreases in successive generations. This has been shown to occur in a number of

inherited neurodegenerative disorders, including Huntington disease [4]. There is some evidence, albeit inconsistent, to suggest genetic anticipation for CRC in Lynch syndrome [5].

The assessment of anticipation for any disease is complicated because it is well known that the false appearance of genetic anticipation may be caused by various forms of ascertainment bias. In cross-sectional studies, individuals from earlier generations are always older than their offspring by definition, and have therefore lived through more of their period at risk. Subjects from later generations who have not yet manifest the disease are excluded from the analysis even though they may have gone on to develop the disease later in their life, thereby lowering the apparent average age of onset in the more recent generation. This is referred to as follow up bias [6]. Similarly, families with predominantly younger diagnoses in later generations are preferentially identified as being at high risk for Lynch syndrome (and are therefore more likely to be included in family cancer registries) compared with families with predominantly older patients in later generations (this occurs because individuals in later generations have not lived long enough to detect cancers that may develop later in their lives [7, 8]).

Another potential cause of apparent anticipation is referred to as fecundity bias. This occurs if the disease adversely affects fertility, so individuals who develop the disease at a younger age are likely to have fewer children than those who are diagnosed at an older age. No previous studies of anticipation in Lynch syndrome (or to our knowledge any inherited cancer) have examined whether fecundity bias can mimic genetic anticipation, and therefore be the explanation for any apparent anticipation.

The purpose of this study was (1) to determine the effect of age of onset of CRC on fertility in Lynch syndrome, (2) to determine by computer simulation whether observed changes in fertility can falsely create the appearance of genetic anticipation, and to what extent, (3) to compare the results of that simulation with the observed appearance of genetic anticipation in a large series of families with Lynch syndrome.

Methods

The Australasian Colorectal Cancer Family Registry (ACCFR) is a registry of more than 11,500 people from 1,800 families in Australia and New Zealand [9]. This registry contains CRC families recruited through the Victorian Cancer Registry (960 population-based case-families) and from family cancer clinics throughout Australia and New Zealand (580 clinic-based case-families), as well as families of people without CRC recruited through the Victorian electoral roll (270 control-families). For all family members, personal and family history of cancer, reproductive history, and other lifestyle and personal characteristics were collected by questionnaire. Attempts were made to verify all reports of CRC diagnoses by medical records, pathology reports, death certificates and linkage to national cancer registry and death registry databases.

Individuals who had developed CRC, and who were members of families known to carry MMR gene mutations (Lynch syndrome families) were categorised by age of diagnosis of CRC. Cohort fertility (the mean number of children born to each individual by the end of their reproductive life- defined as over the age of 50 years) was calculated for each age group of CRC diagnosis (for both men and women). We only included subjects born before 1963 in this analysis in order to include only those who had completed their period of potential fertility.

Model design

A computer model was designed to simulate the age of diagnosis of CRC in large numbers of hypothetical MMR gene mutation carrying men and women (first generation) and their offspring (second generation). The model assumed complete follow-up over the lifetime for all individuals, and assumed the age distribution of CRC diagnoses to be the same across generations (i.e. that there was no genetic anticipation). Because follow up was over the entire lifetime of the hypothetical subjects in both generations, and the complete lifetime risk was applied to each subject, follow up (ascertainment) bias will not cause the appearance of genetic anticipation in this model. In this setting any apparent genetic anticipation would be an artefact.

The model generated an equal number of men and women in the first generation, and allocated gender at random (with a 50:50 chance) to the second generation individuals.

Age of diagnosis of first CRC was randomly assigned according to the (gender-specific) observed distribution of age of first CRC diagnosis from the ACCFR cohort. The number of offspring born to each first generation carrier was randomly assigned according to the observed (gender-specific) distribution of lifetime fertility according to the age of diagnosis of CRC as calculated above. Each second generation individual was given a 50 % chance of inheriting the MMR gene mutation. For each mutation-carrying child, age of diagnosis of first CRC was allocated in the same way as for their parents. The simulation was run for 1,000 first generation subjects. Ages of diagnoses of CRC were compared between the simulated parents and their affected children.



Fig. 1 Cohort (lifetime) fertility rates versus age of diagnosis of CRC

Model validation: observed apparent anticipation in the ACCFR cohort

The appearance of genetic anticipation in the ACCFR cohort was sought by comparing the age of diagnosis of first CRC between parents with their affected children ('parent–child pairs'). Parent–child pairs were identified if both the parent and child had been diagnosed with CRC. Subjects were included if they were proven mutation carriers, or if their mutation status was unknown but their family was known to carry a MMR gene mutation. This analysis was repeated using only parent–child pairs in whom the children were born more than 80 years ago. This minimizes the chance of incomplete follow up of the children falsely lowering the apparent age of diagnosis of CRC relative to their parents (follow up bias), and is in keeping with the methodology used by Nilbert et al. [10] to correct for the birth cohort effect that can falsely create the appearance of anticipation.

Statistical analysis

Mean age of diagnosis of first CRC was compared using the Student's t test. A P—value of 0.05 was regarded as statistically significant. Correlation was determined using Spearman's rank method. Statistical analysis was done using MedCalc for Windows (MedCalc Software, Ostend, Belgium). All results are stated as mean ± SE of the mean unless otherwise specified.

Ethical approval for the study was granted by the University of Melbourne Ethics Committee.

Results

Cohort fertility in the ACCFR

The ACCFR database contained complete data for 9,351 members of 295 families known to carry Lynch syndrome mutations. Of these, 1,088 patients (568 men and 520 women) have been diagnosed with CRC. The mean age of diagnosis of CRC was 46.8 ± 14.3 year (46.3 ± 13.3 for the men, and 47.3 ± 15.4 for the women, $P = 0.24$).

A total of 981 (512 male and 469 female) patients with CRC were born before 1963, and the cohort fertility rates were calculated from this group. Cohort fertility grouped by age of diagnosis of CRC is illustrated in Fig. 1. Total lifetime (cohort) fertility was related to age of diagnosis of CRC in men (correlation coefficient 0.143, $P = 0.0012$), women (correlation coefficient 0.104, $P = 0.04$) and overall (correlation coefficient 0.13, $P = 0.0001$).

Simulation

Using the above parameters, the simulation was run for 1,000 first generation mutation carriers. This generated 1,169 simulated offspring who were mutation carriers. The mean difference in age of diagnosis of first CRC between simulated parents and their mutation positive offspring (apparent anticipation) was 1.8 ± 0.54 years ($P = 0.0044$). Apparent anticipation was similar for male (1.1 ± 0.77) and female (1.9 ± 0.72) simulated parents ($P = 0.44$).

Apparent anticipation in the ACCFR cohort

A total of 461 parent–child pairs with CRC were identified within the ACCFR study cohort. The mean age of diagnosis of first CRC was 51.1 ± 0.63 years in the parent group, and 42.3 ± 0.56 years in their children ($P < 0.0001$). When we included only those parent child pairs with a potential follow up of over 80 years (i.e. only subjects born before 1933), 120 parent–child pairs were identified. In this group, the mean age of diagnosis of first CRC was 53.9 ± 0.68 in the parent group, and 49.1 ± 0.67 in their children (apparent anticipation 4.8 ± 1.73 years, $P = 0.0064$). There was no significant difference in apparent anticipation between the simulated (1.8 years) and observed (4.8 years) parent–child pairs ($P = 0.89$).

Discussion

This simulation demonstrates that the appearance of genetic anticipation in Lynch syndrome can be created due to changes in lifetime fertility in MMR gene mutation carriers with CRC. The apparent anticipation predicted by the model was not significantly different from the observed appearance of anticipation in the AFCCS families with Lynch syndrome which was in keeping with the observed anticipation in large studies of the Danish HNPCC registry of between 3 and 9 years published by Larson et al. [11] and Boonstra et al. [8].

We observed a marked decrease in lifetime fertility in mutation carriers with early diagnosis of CRC compared with those who developed CRC later in life. For example, women diagnosed with CRC between ages 20 and 24 years gave birth to a mean of 1.2 children in their lifetime compared with women diagnosed with CRC after age 50 years who gave birth to a mean of 2.8 children in their lifetime. The reasons for the reduction in fertility after CRC in these patient groups have not been studied here, but cancer-related mortality and morbidity, the effects of surgery, chemotherapy and radiotherapy, and personal choice can all be expected to play a role. We are unaware of any previous studies that have documented fertility rates after CRC in Lynch syndrome although reduced fertility is well recognized in patients who receive chemotherapy or radiotherapy, and suspected to occur after surgery for CRC [12]. It is this reduction in fertility that contributed to apparent anticipation in our model.

A number of authors have studied genetic anticipation in Lynch syndrome, with differing conclusions as to whether it occurs and to what extent (this literature is summarized in Table 1). Tsai et al. [13], Westphalen et al. [14] and Stupart et al. [15] found no evidence of genetic anticipation, but others have reported its occurrence [7, 8, 10, 11, 16–19]. There is variability in the degree of reported anticipation (from 3 to 10 years) even when similar patient registries have been analysed using different methods.

A potential cause for apparent genetic anticipation is follow- up bias [6]. This can be corrected for by including

Table 1 Previously published studies reporting the presence or absence of genetic anticipation in Lynch syndrome

Paper	Data set	Numbers	Average anticipation (years)
Warthin [16]	"Famliy G"	28 patients with CRC over four generations	8
Vasen et al. [17]	Foundation for the detection of hereditary tumours (Netherlands)	74 patients with CRC over three generations	8.5
Rodriguez-Bigas [18]	Roswell Park Cancer Institute HNPCC Registry	193 patients with CRC	5.5
Tsai et al. [13]	Johns Hopkins Hereditary Colorectal Cancer Registry	67 parent–child pairs with CRC*	0
Voskuil et al. [7]	Foundation for the Detection of hereditary tumours (Netherlands)	1,186 subjects	0
Westphalen et al. [14]	University of Basel and Institut Central des Hopitaux Valaisans registries	55 parent–child pairs with CRC	8
Stella et al. [19]	Five Italian families	24 parent–child pairs with CRC	11
Larsen et al. [11]	Danish HNPCC Registry	824 subjects	3
Nilbert et al. [10]	Danish HNPCC Registry	290 parent–child pairs with CRC	5.5–9.8
Boonstra et al. [8]	Danish HNPCC Registry	816 subjects or 290 parent–child pairs with CRC	3 or 8.7
Boonstra et al. [8]	University of Michigan Cancer Genetics Clinic	136 parent–child pairs with CRC	9.9
Stupart et al. [15]	Single South African family	92 mutation carriers	0

Boonstra et al. [8] described findings from two different patient sets in the same article. Nilbert et al. [10] and Boonstra et al. [8] found different degrees of apparent anticipation depending on the statistical method used to analyze the data sets

only subjects who were born sufficiently long ago that they have completed their period at risk [10] (in this case by including only subjects (from both generations) who were born at least 80 years ago). This type of bias cannot fully explain the observed appearance of anticipation in parent–child pairs from the ACCFR as it still existed when we only included mutation carriers with more than 80 years of potential follow up (i.e. born before 1933). This is in keeping with the findings of Nilbert et al. [10], whereas Tsai et al. [13] found no difference in age of diagnosis of CRC between parents and their children when the birth cohort effect was taken into account.

We included subjects with CRC who were not proven MMR gene mutation carriers (but were from families known to carry MMR gene mutations) as well as those who were confirmed to carry mutations in the MMR genes, in keeping with the methodology of previous authors [10, 13]. This was to allow inclusion of a sufficient number of patients with adequate potential follow up. One would expect the great majority of subjects with CRC born before 1933 to have died before mutation analysis became available. In the ACCFR database, there were 2,128 individuals born before 1933, of whom 433 (20.3 %) were diagnosed with CRC. Of these 433, only 59 (13.6 %) have undergone genetic testing.

Actual genetic anticipation does occur in several neurodegenerative disorders, including Huntington disease [4] and spinocerebellar ataxia [20–22] by the molecular mechanism of generational expansion of trinucleotide repeats during meiosis and gametogenesis [23]. In Li-Fraumeni syndrome, anticipation has been found to be associated with decreasing telomere length over generations [24]. There is no evidence that this occurs in Lynch syndrome, and in a mouse model of Huntington disease MMR gene deficiency has been shown to prevent this from occurring [25]. It has been hypothesised that germline MMR gene defects may lead to an accumulation of small errors in DNA replication prior to loss of heterozygosity which could be passed on over the generations but direct evidence that this occurs is lacking [23]. Bozzao et al. [26] have recently described abnormalities in telomere length in carriers of *MSH2* mutations, but not *MLH1* mutation carriers. This is a developing area of research, but a definite molecular mechanism for anticipation in Lynch syndrome (if it occurs) has yet to be found.

In conclusion, we have shown that fecundity bias can falsely create the appearance of genetic anticipation in Lynch syndrome. This highlights the statistical complexity of studying genetic anticipation and the ongoing uncertainty of whether the phenomenon occurs in this disease.

References

1. Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, Wang F, Bandipalliam P, Syngal S, Gruber SB (2009) Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 137(5):1621–1627
2. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CLY, Ruhl MJ, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, and Cronin KA (2013) SEER cancer statistics review, 1975–2010, based on November 2012 SEER data submission, posted to the SEER web site, April 2013. [cited 2013 4 September 2013]; http://seer.cancer.gov/csr/1975_2010
3. Watson P, Riley B (2005) The tumour spectrum in the Lynch syndrome. Fam Cancer 4(3):245–248
4. Rubinsztein DC, Amos W, Leggo J, Goodburn S, Ramesar RS, Old J, Bontrop R, McMahon R, Barton DE, Ferguson-Smith MA (1994) Mutational bias provides a model for the evolution of Huntington's disease and predicts a general increase in disease prevalence. Nat Genet 7(4):525–530
5. Gruber SB, Mukherjee B (2009) Anticipation in lynch syndrome: still waiting for the answer. J Clin Oncol 27(3):326–327
6. Picco MF, Goodman S, Reed J, Bayless TM (2001) Methodologic pitfalls in the determination of genetic anticipation: the case of Crohn disease. Ann Intern Med 134(12):1124–1129
7. Voskuil DW, Vasen HF, Kampman E, van't Veer P (1997) Colorectal cancer risk in HNPCC families: development during lifetime and in successive generations. National Collaborative Group on HNPCC. Int J Cancer 72(2):205–209
8. Boonstra PS, Gruber SB, Raymond VM, Huang SC, Timshel S, Nilbert M, Mukherjee B (2010) A review of statistical methods for testing genetic anticipation: looking for an answer in Lynch syndrome. Genet Epidemiol 34(7):756–768
9. Winship I, Win AK (2012) The Australasian colorectal cancer family registry. Med J Aust 197(9):480–481
10. Nilbert M, Timshel S, Bernstein I, Larsen K (2009) Role for genetic anticipation in Lynch syndrome. J Clin Oncol 27(3):360–364
11. Larsen K, Petersen J, Bernstein I, Nilbert M (2009) A parametric model for analysing anticipation in genetically predisposed families. Stat Appl Genet Mol Biol 8:Article26
12. O'Neill MT, Dhonnchu TN, Brannigan AE (2011) Topic update: effects of colorectal cancer treatments on female fertility and potential methods for fertility preservation. Dis Colon Rectum 54(3):363–369
13. Tsai YY, Petersen GM, Booker SV, Bacon JA, Hamilton SR, Giardiello FM (1997) Evidence against genetic anticipation in familial colorectal cancer. Genet Epidemiol 14(4):435–446
14. Westphalen AA, Russell AM, Buser M, Berthod CR, Hutter P, Plasilova M, Mueller H, Heinimann K (2005) Evidence for genetic anticipation in hereditary non-polyposis colorectal cancer. Hum Genet 116(6):461–465
15. Stupart D, Goldberg P, Algar U, Vorster A, and Ramesar R (2013) No evidence of genetic anticipation in a large family with Lynch syndrome. Fam Cancer 13(1):29–34
16. Warthin AS (1925) The further study of a cancer family. J Cancer Res 9:279–286
17. Vasen HF, Taal BG, Griffioen G, Nagengast FM, Cats A, Menko FH, Oskam W, Kleibeuker JH, Offerhaus GJ, Khan PM (1994) Clinical heterogeneity of familial colorectal cancer and its influence on screening protocols. Gut 35(9):1262–1266
18. Rodriguez-Bigas MA, Lee PH, O'Malley L, Weber TK, Suh O, Anderson GR, Petrelli NJ (1996) Establishment of a hereditary

nonpolyposis colorectal cancer registry. Dis Colon Rectum 39(6):649–653
19. Stella A, Surdo NC, Lastella P, Barana D, Oliani C, Tibiletti MG, Viel A, Natale C, Piepoli A, Marra G, Guanti G (2007) Germline novel MSH2 deletions and a founder MSH2 deletion associated with anticipation effects in HNPCC. Clin Genet 71(2):130–139
20. Ranum LP, Chung MY, Banfi S, Bryer A, Schut LJ, Ramesar R, Duvick LA, McCall A, Subramony SH, Goldfarb L (1994) Molecular and clinical correlations in spinocerebellar ataxia type I: evidence for familial effects on the age at onset. Am J Hum Genet 55(2):244–252
21. Ramesar RS, Bardien S, Beighton P, Bryer A (1997) Expanded CAG repeats in spinocerebellar ataxia (SCA1) segregate with distinct haplotypes in South African families. Hum Genet 100(1):131–137
22. Bryer A, Krause A, Bill P, Davids V, Bryant D, Butler J, Heckmann J, Ramesar R, Greenberg J (2003) The hereditary adult-onset ataxias in South Africa. J Neurol Sci 216(1):47–54
23. Bozzao C, Lastella P, Stella A (2011) Anticipation in lynch syndrome: where we are where we go. Curr Gen 12(7):451–465
24. Tabori U, Nanda S, Druker H, Lees J, Malkin D (2007) Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res 67(4):1415–1418
25. Manley K, Shirley TL, Flaherty L, Messer A (1999) Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice. Nat Genet 23(4):471–473
26. Bozzao C, Lastella P, Ponz de Leon M, Pedroni M, Di Gregorio C, D'Ovidio FD, Resta N, Prete F, Guanti G, Stella A (2011) Analysis of telomere dynamics in peripheral blood cells from patients with Lynch syndrome. Cancer 117(18):4325–4335